Genocea’s mission is to harness human biology to develop cancer immunotherapies for any patient by unlocking the targets that matter most. Our proprietary ATLAS™ technology is a clinically-validated platform that uniquely profiles the T cell repertoire and tumors, by selecting the therapeutically relevant antigens that drive powerful anti-tumor immune responses. ATLAS™ is the only platform able to identify Inhibigens™, or inhibitory antigens that dampen the immune response.

ATLAS™ drives Genocea’s emerging immunotherapy pipeline of best-in-class clinical stage programs. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Jun 04, 2021
Genocea Presents Promising Long-term Results from GEN-009 Neoantigen Vaccine Phase 1 Trial at ASCO 2021
Four of nine checkpoint inhibitor-sensitive patients experienced RECIST responses post vaccination; median duration without disease progression after initial GEN-009 vaccination was 15 months Two of seven CPI-refractory patients experienced stable disease for up to 10 months after initial GEN-009 READ MORE >
Apr 29, 2021
Genocea Provides First Quarter 2021 Corporate Update
GEN-011 and GEN-009 immuno-oncology programs continue to advance Research on Inhibigens ™ and SARS-CoV-2 continues to progress Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass. , April 29, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company READ MORE >
Apr 22, 2021
Genocea To Host First Quarter 2021 Corporate Update Conference Call & Webcast
CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its first quarter 2021 financial results and corporate update conference call and live audio webcast on READ MORE >

Event and Presentations

Genocea presents regularly at top-tier scientific and investor conferences.

Events image
Upcoming Event
Jun 24, 2021 9:00 AM EDT
Annual Shareholder Meeting
Listen to webcast
Events image
Past Event
Apr 29, 2021 8:30 AM EDT
First Quarter 2021 Financial Results
Listen to webcast

Corporate Governance

The Board of Directors of Genocea Biosciences (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Financials and Filings

Contact Us